Genta Incorporated engages in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases in the United States. The company’s research portfolio consists of two major programs: DNA/RNA Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys, aptamers, and small interfering or micro RNA. Its product Genasense, designed to block the production of a protein known as Bcl-2, which is used for the treatment of malignant melanoma, chronic lymphocytic...